A Study to Assess Prevalence of a Specific Protein Overexpression in Adult Participants With Non-Small Cell Lung Cancer

AbbVie579 enrolled

Overview

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for 80%-85% of lung cancers cases of which 60% are non-squamous (NSQ). This study will evaluate the prevalence of mesenchymal epithelial transition (MET) overexpression (OE) in adult participants with advanced or metastatic NSQ NSCLC. Archived tissue biopsies will be tested for MET OE and data from approximately 500 participants will be collected. No participants will be enrolled in this study. Participants' charts will be reviewed. No drug will be administered as a part of this study. The duration of the study will be approximately 15 months. There is no additional burden for participants in this trial.

Study Type

OBSERVATIONAL

Enrollment

579

Conditions

Non Small Cell Lung Cancer

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Previously consented and/or prospective collection of consent for research use of banked biological materials and clinical data. * Confirmed advanced and/or metastatic non-squamous (NSQ) non-small cell lung cancer (NSCLC). * Has formalin-fixed paraffin-embedded (FFPE) tissue collected since 2019. Exclusion Criteria: * Specimens collected before 2019. * Insufficient specimen tissue for testing. * Insufficient specimen quality (e.g., not 4-5 µm in thickness) which precludes testing. * Adenosquamous and sarcomatous histologies of NSCLC.

Locations (19)

Hospital Italiano de Buenos Aires /ID# 256999

Ciudad Autonoma Buenos Aires, Buenos Aires F.D., Argentina

Instituto Alexander Fleming /ID# 256295

Ciudad Autonoma de Buenos Aire, Buenos Aires F.D., Argentina

Irmandade da Santa Casa de Misericordia de Porto Alegre /ID# 256487

Porto Alegre, Rio Grande do Sul, Brazil

Hospital Alemao Oswaldo Cruz /ID# 256486

São Paulo, Brazil

Nova Scotia Health Authority /ID# 256950

Halifax, Nova Scotia, Canada

Institut universitaire de cardiologie et de pneumologie de Québec - Université L /ID# 257872

Québec, Quebec, Canada

Royal University Hospital /ID# 261272

Saskatoon, Saskatchewan, Canada

West China Hospital, Sichuan University /ID# 256906

Chengdu, Sichuan, China

Rambam Health Care Campus /ID# 256546

Haifa, H_efa, Israel

Kindai University Hospital /ID# 257890

Osakasayama-shi, Osaka, Japan

...and 9 more locations

Outcomes

Primary Outcomes

Presence of Mesenchymal Epithelial Transition (MET) protein overexpression (OE)

OE is defined as: positive: \>= 25% of tumor cells with 3+ staining intensity, or negative: \< 25% of tumor cells with 3+ staining intensity. High overexpression (OE high) is defined as: positive: \>= 50% of tumor cells with 3+ staining intensity negative: \< 50% of tumor cells with 3+ staining intensity. These are determined by an immunohistochemistry (IHC) performed by the local laboratory.

Time frame: Up to 15 Months